Huntleigh Advisors Inc. Boosts Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Huntleigh Advisors Inc. increased its position in ADMA Biologics Inc (NASDAQ:ADMA) by 9.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 109,616 shares of the biotechnology company’s stock after buying an additional 9,687 shares during the quarter. Huntleigh Advisors Inc.’s holdings in ADMA Biologics were worth $2,175,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Mark Sheptoff Financial Planning LLC acquired a new position in ADMA Biologics in the 4th quarter worth $35,000. Vision Financial Markets LLC purchased a new position in ADMA Biologics in the fourth quarter valued at about $51,000. Tsfg LLC acquired a new stake in ADMA Biologics during the 1st quarter valued at approximately $51,000. Farther Finance Advisors LLC grew its stake in ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in ADMA Biologics during the 4th quarter worth approximately $84,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADMA has been the subject of several research analyst reports. Raymond James Financial increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th.

ADMA Biologics Stock Up 0.9%

ADMA stock opened at $18.30 on Friday. The firm has a fifty day moving average price of $20.32 and a two-hundred day moving average price of $18.73. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. ADMA Biologics Inc has a 1-year low of $10.21 and a 1-year high of $25.67. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 21.52 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the company earned $0.08 EPS. ADMA Biologics’s revenue was up 40.2% compared to the same quarter last year. Research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Buying and Selling

In related news, Director Steve Elms sold 194,749 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,621 shares of company stock valued at $9,644,269. Insiders own 3.50% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.